Stock Events

Stock Events

Avalo Therapeutics 

$20.33
92
+$0.62+3.13% 13:02 Today

Statistics

Day High
19.74
Day Low
19.71
52W High
24.27
52W Low
8.41
Volume
20,341
Avg. Volume
-
Mkt Cap
1.06B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.3
-1.59
-0.88
-0.17
Expected EPS
-0.563367
Actual EPS
N/A

Financials

-132,642.37%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
59,000Revenue
-78.26MNet Income

Analyst Ratings

45.89Average Price Target
The highest estimate is 60.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVTX. It's not an investment recommendation.
Tesla
16
TSLA
Microsoft
14
MSFT
Amazon
14
AMZN
NVIDIA
14
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is a competitor due to its focus on creating transformative medicines for people with serious diseases, similar to Avalo's mission in the biotech space.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences competes in the development of treatments for life-threatening diseases, overlapping with Avalo's therapeutic areas.
AMGEN
AMGN
Mkt Cap224.63B
Amgen operates in the biotechnology industry focusing on human therapeutics, directly competing with Avalo's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for serious conditions, aligning with Avalo's goals.
Biogen
BIIB
Mkt Cap31B
Biogen focuses on neurology and rare diseases, areas that Avalo could potentially explore, making them competitors.
Incyte
INCY
Mkt Cap24.36B
Incyte Corporation works on small molecule drugs for oncology and inflammation, areas that could intersect with Avalo's interests.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, a novel area of medicine that could compete with Avalo's innovative approaches.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge area of biotech that could rival Avalo's therapeutic innovations.

About

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Show more...
CEO
Garry A. Neil
Employees
33
Country
United States
ISIN
US05338F3064
WKN
000A3E2FR

Listings

XNAS
US
AVTX
STU
DE
C6K0.STU
MU
DE
C6K0.MU
F
DE
C6K0.F

0 Comments

Share your thoughts

FAQ

What is Avalo Therapeutics stock price today?▼
The current price of AVTX is $20.33 USD — it has increased by +3.13% in the past 24 hours. Watch Avalo Therapeutics stock price performance more closely on the chart.
What is Avalo Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Avalo Therapeutics stocks are traded under the ticker AVTX.
Is Avalo Therapeutics stock price growing?▼
AVTX stock has risen by +0.82% compared to the previous week, the month change is a +1.76% rise, over the last year Avalo Therapeutics has showed a +121.59% increase.
What is Avalo Therapeutics market cap?▼
Today Avalo Therapeutics has the market capitalization of 1.06B
When is the next Avalo Therapeutics earnings date?▼
Avalo Therapeutics is going to release the next earnings report on November 05, 2026.
What were Avalo Therapeutics earnings last quarter?▼
AVTX earnings for the last quarter are -0.83 USD per share, whereas the estimation was -0.58 USD resulting in a -42.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Avalo Therapeutics revenue for the last year?▼
Avalo Therapeutics revenue for the last year amounts to 59,000 USD.
What is Avalo Therapeutics net income for the last year?▼
AVTX net income for the last year is -78.26M USD.
How many employees does Avalo Therapeutics have?▼
As of August 19, 2026, the company has 33 employees.
In which sector is Avalo Therapeutics located?▼
Avalo Therapeutics operates in the Health & Wellness sector.
When did Avalo Therapeutics complete a stock split?▼
The last stock split for Avalo Therapeutics was on December 29, 2023 with a ratio of 1:240.
Where is Avalo Therapeutics headquartered?▼
Avalo Therapeutics is headquartered in WAYNE, United States.